Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| SELLAS Life Sciences Group, Inc.GALE · Entity 4313 | Chief Medical Officer | January 17, 2017 | January 19, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
SELLAS Life Sciences Group, Inc.
Report date January 17, 2017 · Filed January 19, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.81 · Expires 2027-01-17 | Direct | 30,000 |
Reported balance
After 2017-01-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-01-17 · Grant · Acquired 30,000 · Balance 30,000 F1: Granted pursuant to the Issuer's 2016 Incentive Plan. F2: This stock option will vest in 16 equal, quarterly installments over four years, beginning three months from the date of grant, so long as the Reporting Person remains in the company's continuous employ through the vesting period. |
Filing footnotes · ownership attribution and instrument terms
F1: Granted pursuant to the Issuer's 2016 Incentive Plan.
F2: This stock option will vest in 16 equal, quarterly installments over four years, beginning three months from the date of grant, so long as the Reporting Person remains in the company's continuous employ through the vesting period.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 17, 2017 Filed Jan 19, 2017 19:44 UTC | SELLAS Life Sciences Group, Inc. GALE · Entity 4313 | GrantStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $1.81 | $0.00 |
DisclosureSEC source: 0001394548-17-000003 · primary_doc.xml · derivative · entry 1 Nejadnik Bijan · CIK 0001657705 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2027-01-17 F1 · security: Granted pursuant to the Issuer's 2016 Incentive Plan. F2 · derivative.exercise_date: This stock option will vest in 16 equal, quarterly installments over four years, beginning three months from the date of grant, so long as the Reporting Person remains in the company's continuous employ through the vesting period. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.